Nutritional Advice El Mondo
Objectives:
The efficacy of dendritic cell vaccine for newly diagnosed glioblastoma remains controversial. Therefore, this review article has been conducted.
Does dendritic cell vaccine provide benefits for the newly diagnosed glioblastoma?
Study design:
This review article included 3 randomized controlled trials (RCTs).
Results and conclusions:
The investigators found overall, compared with control group for newly diagnosed glioblastoma, dendritic cell vaccine showed no substantial effect on:
-median overall survival [SMD = 0.11, 95% CI = -0.18 to 0.41, p = 0.45];
-median progression-free survival [SMD = 0.12, 95% CI = -0.24 to 0.48, p = 0.50];
-progression-free survival rate [risk ratio = 1.29, 95% CI = 0.82 to 2.04, p = 0.27];
-overall survival rate [risk ratio = 1.29, 95% CI = 0.61 to 2.72, p = 0.50] or;
-nervous system disorders [risk ratio = 0.80, 95% CI= 0.59 to 1.08, p = 0.14].
The investigators concluded dendritic cell vaccine provides no obvious benefits for the newly diagnosed glioblastoma.
Original title:
The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies by Tan L, Peng J, […], Wu Q.
Link:
https://pubmed.ncbi.nlm.nih.gov/34767325/
Additional information of El Mondo:
Find more information/studies on RCTs/cohort/significantly/review article and cancer right here.
Dendritic cells (DCs) are professional antigen-presenting cells that link innate and adaptive immunity and are critical for the induction of protective immune responses against pathogens.
Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord.